MAPI (Mapi - Pharma) 10-Year Sharpe Ratio : N/A (As of Apr. 23, 2025)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma 10-Year Sharpe Ratio?

The 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. As of today (2025-04-23), Mapi - Pharma's 10-Year Sharpe Ratio is Not available.

Competitive Comparison of Mapi - Pharma's 10-Year Sharpe Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's 10-Year Sharpe Ratio, along with its competitors' market caps and 10-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mapi - Pharma's 10-Year Sharpe Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's 10-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's 10-Year Sharpe Ratio falls into.

Save Embed

;

Save Embed

;

Mapi - Pharma 10-Year Sharpe Ratio Calculation

The 10-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last ten years. A stock / portfolio's 10-Year Sharpe Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past ten years.

Mapi - Pharma (NAS:MAPI) 10-Year Sharpe Ratio Explanation

The 10-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past ten years. It is calculated as the annualized result of the average ten-year monthly excess returns divided by its standard deviation in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Mapi - Pharma 10-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's 10-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » 10-Year Sharpe Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.